Cargando…

Acute dosing of latrepirdine (Dimebon™), a possible Alzheimer therapeutic, elevates extracellular amyloid-β levels in vitro and in vivo

BACKGROUND: Recent reports suggest that latrepirdine (Dimebon™, dimebolin), a retired Russian antihistamine, improves cognitive function in aged rodents and in patients with mild to moderate Alzheimer's disease (AD). However, the mechanism(s) underlying this benefit remain elusive. AD is charac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Steele, John W, Kim, Soong H, Cirrito, John R, Verges, Deborah K, Restivo, Jessica L, Westaway, David, Fraser, Paul, Hyslop, Peter St George, Sano, Mary, Bezprozvanny, Ilya, Ehrlich, Michelle E, Holtzman, David M, Gandy, Sam
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2806870/ https://www.ncbi.nlm.nih.gov/pubmed/20017949 http://dx.doi.org/10.1186/1750-1326-4-51

Ejemplares similares

Differences in bioavailability and cognitive-enhancing activity exerted by different crystal polymorphs of latrepirdine (Dimebon(®))
por: Gorin, Boris I., et al.
Publicado: (2023)

A bioisostere of Dimebon/Latrepirdine delays the onset and slows the progression of pathology in FUS transgenic mice
por: Chaprov, Kirill, et al.
Publicado: (2021)

Evaluation of Dimebon in cellular model of Huntington's disease
por: Wu, Jun, et al.
Publicado: (2008)

Mitochondrial Pharmacology of Dimebon (Latrepirdine) Calls for a New Look at its Possible Therapeutic Potential in Alzheimer’s Disease
por: Eckert, Schamim H, et al.
Publicado: (2018)

Design, Synthesis, Molecular Docking Study and Biological Evaluation of Novel γ-Carboline Derivatives of Latrepirdine (Dimebon) as Potent Anticancer Agents
por: Voggu, Ramakrishna, et al.
Publicado: (2023)

The Effects of Latrepirdine on Amyloid-β Aggregation and Toxicity
por: Porter, Tenielle, et al.
Publicado: (2016)

Latrepirdine stimulates autophagy and reduces accumulation of α-synuclein in cells and in mouse brain
por: Steele, John W., et al.
Publicado: (2012)

Dimebon disappointment
por: Jones, Roy W
Publicado: (2010)

Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseases
por: Bharadwaj, P R, et al.
Publicado: (2013)

Preclinical study of dimebon on β-amyloid-mediated neuropathology in Alzheimer's disease
por: Wang, Jun, et al.
Publicado: (2011)

The isotropic fractionator provides evidence for differential loss of hippocampal neurons in two mouse models of Alzheimer's disease
por: Brautigam, Hannah, et al.
Publicado: (2012)

Dietary composition modulates brain mass and solubilizable Aβ levels in a mouse model of aggressive Alzheimer's amyloid pathology
por: Pedrini, Steve, et al.
Publicado: (2009)

Dimebon Slows Progression of Proteinopathy in γ-Synuclein Transgenic Mice
por: Bachurin, Sergey O., et al.
Publicado: (2011)

AMPA-ergic regulation of amyloid-β levels in an Alzheimer’s disease mouse model
por: Hettinger, Jane C., et al.
Publicado: (2018)

Latrepirdine is a potent activator of AMP-activated protein kinase and reduces neuronal excitability
por: Weisová, P, et al.
Publicado: (2013)

Presenilin 1 Controls γ-Secretase Processing of Amyloid Precursor Protein in Pre-Golgi Compartments of Hippocampal Neurons
por: Annaert, Wim G., et al.
Publicado: (1999)

Neuronal activity regulates the regional vulnerability to amyloid-β deposition
por: Bero, Adam W., et al.
Publicado: (2011)

Amyloid β perturbs elevated heme flux induced with neuronal development
por: Vidal, Chantal, et al.
Publicado: (2019)

Lysosomal dysfunction in the brain of a mouse model with intraneuronal accumulation of carboxyl terminal fragments of the amyloid precursor protein
por: Kaur, Gurjinder, et al.
Publicado: (2016)

Reactive or transgenic increase in microglial TYROBP reveals a TREM2‐independent TYROBP–APOE link in wild‐type and Alzheimer's‐related mice
por: Audrain, Mickael, et al.
Publicado: (2020)

Integrative approach to sporadic Alzheimer’s disease: deficiency of TYROBP in a tauopathy mouse model reduces C1q and normalizes clinical phenotype while increasing spread and state of phosphorylation of tau
por: Audrain, Mickael, et al.
Publicado: (2018)

Breaking Up (Amyloid) Is Hard to Do
por: Gandy, Sam, et al.
Publicado: (2005)

Cytoskeleton Protein EB3 Contributes to Dendritic Spines Enlargement and Enhances Their Resilience to Toxic Effects of Beta-Amyloid
por: Pchitskaya, Ekaterina, et al.
Publicado: (2022)

Dimebon Does Not Ameliorate Pathological Changes Caused by Expression of Truncated (1–120) Human Alpha-Synuclein in Dopaminergic Neurons of Transgenic Mice
por: Shelkovnikova, Tatyana A., et al.
Publicado: (2011)

News & views: anti-amyloid antibodies and novel emerging approaches to Alzheimer’s disease in 2023
por: Gandy, Sam
Publicado: (2023)

Anti-Amyloid-β-Mediated Positron Emission Tomography Imaging in Alzheimer's Disease Mouse Brains
por: McLean, Daniel, et al.
Publicado: (2012)

Open peer commentary on “Prescribing anti‐amyloid immunotherapies to treat Alzheimer's disease: Fully informing patient decisions”
por: Gandy, Sam
Publicado: (2023)

Rapid in vivo measurement of β-amyloid reveals biphasic clearance kinetics in an Alzheimer’s mouse model
por: Yuede, Carla M., et al.
Publicado: (2016)

STIM2 protects hippocampal mushroom spines from amyloid synaptotoxicity
por: Popugaeva, Elena, et al.
Publicado: (2015)

TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques
por: Wang, Yaming, et al.
Publicado: (2016)

ApoE Alzheimer’s Disease Aβ-amyloid plaque morphology varies according to APOE isotype
por: Caesar, Ina, et al.
Publicado: (2023)

Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA
por: Gandy, Sam, et al.
Publicado: (2021)

Rapid doubling of Alzheimer’s amyloid-β40 and 42 levels in brains of mice exposed to a nickel nanoparticle model of air pollution
por: Kim, Soong Ho, et al.
Publicado: (2012)

Alzheimer mutant speeds APP transport
por: Gandy, Sam, et al.
Publicado: (2021)

miR155, TREM2, INPP5D: Disease stage and cell type are essential considerations when targeting clinical interventions based on mouse models of Alzheimer’s amyloidopathy
por: Gandy, Sam, et al.
Publicado: (2023)

Correction: miR155, TREM2, INPP5D: Disease stage and cell-type are essential considerations when targeting clinical interventions based on mouse models of Alzheimer’s amyloidopathy
por: Gandy, Sam, et al.
Publicado: (2023)

Redundant G(s)-coupled serotonin receptors regulate amyloid-β metabolism in vivo
por: Fisher, Jonathan R., et al.
Publicado: (2016)

In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis
por: Ulrich, Jason D, et al.
Publicado: (2013)

Sleep in Alzheimer's Disease–Beyond Amyloid
por: Holth, Jerrah K., et al.
Publicado: (2016)

Current and future implications of basic and translational research on amyloid-β peptide production and removal pathways
por: Bohm, C., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_fqbjq5ja2k6jl6r81naras6vp0